Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 4
1979 1
1980 1
1983 1
1985 1
1986 1
1988 1
1989 1
1990 2
1991 1
1992 1
1994 3
2007 1
2012 1
2017 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Carboplatin is ototoxic.
Kennedy IC, Fitzharris BM, Colls BM, Atkinson CH. Kennedy IC, et al. Among authors: fitzharris bm. Cancer Chemother Pharmacol. 1990;26(3):232-4. doi: 10.1007/BF02897206. Cancer Chemother Pharmacol. 1990. PMID: 2192812
Comparative aspects of the hepatobiliary transport of IgA.
Orlans E, Peppard JV, Payne AW, Fitzharris BM, Mullock BM, Hinton RH, Hall JG. Orlans E, et al. Among authors: fitzharris bm. Ann N Y Acad Sci. 1983 Jun 30;409:411-27. doi: 10.1111/j.1749-6632.1983.tb26886.x. Ann N Y Acad Sci. 1983. PMID: 6575711 No abstract available.
Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.
Carlino MS, Menzies AM, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Guminski AD, Kefford R, Wu H, Ibrahim N, Homet Moreno B, Long GV. Carlino MS, et al. Among authors: fitzharris bm. Clin Cancer Res. 2020 Oct 1;26(19):5086-5091. doi: 10.1158/1078-0432.CCR-20-0177. Epub 2020 Jun 30. Clin Cancer Res. 2020. PMID: 32605909 Clinical Trial.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D; METRIC Study Group. Flaherty KT, et al. N Engl J Med. 2012 Jul 12;367(2):107-14. doi: 10.1056/NEJMoa1203421. Epub 2012 Jun 4. N Engl J Med. 2012. PMID: 22663011 Free article. Clinical Trial.
Lymphoma after S.L.E.
Barrett A, Fitzharris BM, Robson T, Smyth JF. Barrett A, et al. Among authors: fitzharris bm. Lancet. 1978 Nov 18;2(8099):1102. doi: 10.1016/s0140-6736(78)91841-x. Lancet. 1978. PMID: 82122 No abstract available.
Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.
Long GV, Atkinson V, Cebon JS, Jameson MB, Fitzharris BM, McNeil CM, Hill AG, Ribas A, Atkins MB, Thompson JA, Hwu WJ, Hodi FS, Menzies AM, Guminski AD, Kefford R, Kong BY, Tamjid B, Srivastava A, Lomax AJ, Islam M, Shu X, Ebbinghaus S, Ibrahim N, Carlino MS. Long GV, et al. Among authors: fitzharris bm. Lancet Oncol. 2017 Sep;18(9):1202-1210. doi: 10.1016/S1470-2045(17)30428-X. Epub 2017 Jul 17. Lancet Oncol. 2017. PMID: 28729151 Free article. Clinical Trial.
Aminoglutethimide in treatment of metastatic breast carcinoma.
Smith IE, Fitzharris BM, McKinna JA, Fahmy DR, Nash AG, Neville AM, Gazet JC, Ford HT, Powles TJ. Smith IE, et al. Among authors: fitzharris bm. Lancet. 1978 Sep 23;2(8091):646-9. doi: 10.1016/s0140-6736(78)92759-9. Lancet. 1978. PMID: 80576
22 results